All Clarivate Analytics websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
As part of the U.S. cancer moonshot, the Patent and Trademark Office is implementing a one-year pilot program Wednesday to provide for earlier review of patent applications pertaining to cancer immunotherapy. To qualify for the 12-month review, applications must claim a method of treating a cancer using immunotherapy, and the applicant must file a grantable "petition to make special" before June 29, 2017.